Last 1,341 GBp
Change Today -6.50 / -0.48%
Volume 2.1M
GSK On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 4:59 AM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc (GSK) Snapshot

Open
1,354 GBp
Previous Close
1,347 GBp
Day High
1,358 GBp
Day Low
1,336 GBp
52 Week High
02/21/14 - 1,706 GBp
52 Week Low
10/16/14 - 1,297 GBp
Market Cap
65.3B
Average Volume 10 Days
11.3M
EPS TTM
0.87 GBp
Shares Outstanding
4.9B
EX-Date
02/19/15
P/E TM
15.4x
Dividend
88.89 GBp
Dividend Yield
6.62%
Current Stock Chart for GLAXOSMITHKLINE PLC (GSK)

glaxosmithkline plc (GSK) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. The company's total wellness products comprise Panadol for the treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; and ENO Tums, a rapid relief antacid. Its oral care products include Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. The company’s nutrition products comprise Horlicks and Maxinutrition for nutrition; and skin health products include Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases. The company has a strategic cancer immunotherapy collaboration with Adaptimmune Limited to develop and commercialize NY-ESO-1 clinical cancer program. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

99,451 Employees
Last Reported Date: 02/28/14
Founded in 1935

glaxosmithkline plc (GSK) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.9M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.6M GBP
Chairman of Global Vaccines, Executive Direct...
Total Annual Compensation: $3.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline plc (GSK) Key Developments

GlaxoSmithKline Announces Earnings Results for the First Half of 2014

GlaxoSmithKline announced earnings results for the first half of 2014. The company's sales in the first half of 2014 were worse than expected after revealing a turnover of 5.6 billion, down 4% from the same time last year, and core earnings down 12%.

GlaxoSmithKline PLC to Cut Hundreds of US Jobs

GlaxoSmithKline PLC's 17,000 U.S.-based employees will lose their jobs by the end of next year under the pharmaceutical industry's latest restructuring. The company announced it will eliminate about 900 jobs in marketing and research in Research Triangle Park, North Carolina, though some cuts will be made through a hiring freeze and not filling vacant positions. Some positions will be shifted to the company's U.S. headquarters in Philadelphia.

GlaxoSmithKline Drops Plans To Sell Older Drugs Business

GlaxoSmithKline plc (LSE:GSK) said that it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers. GlaxoSmithKline said, "The company has evaluated all bids received and has concluded, consistent with its key criteria of maximising shareholder value, not to pursue divestment of these products." A spokesman for GSK, which was being advised on the disposal by Lazard, declined to give any more details. The sources told Reuters that bidders, who had been hoping to clinch a deal before the end of 2014, included Apollo Global Management, LLC, H. Lundbeck A/S (CPSE:LUN), and KKR & Co. L.P. (NYSE:KKR), which teamed up with Norgine Pharmaceuticals Limited.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:LN 1,340.50 GBp -6.50

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $160.60 USD +1.55
AbbVie Inc $66.57 USD +1.32
Celgene Corp $112.82 USD +2.73
Eli Lilly & Co $70.28 USD +1.02
Novo Nordisk A/S kr264.50 DKK +4.60
View Industry Companies
 

Industry Analysis

GSK

Industry Average

Valuation GSK Industry Range
Price/Earnings 15.3x
Price/Sales 2.7x
Price/Book 12.5x
Price/Cash Flow 15.2x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.